Seattle biotech startup Tune Therapeutics lands $175M to support clinical research

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

The new funding will support Tune’s first clinical trials in New Zealand and Hong Kong, where it’s testing an epigenetic treatment for chronic Hepatitis B. “We have the benefit of standing on the shoulders of a lot of the cell and genomic medicine companies that have come along the way over the last 15 years or so,” said Akira Matsuno, Tune’s co-founder and chief financial officer.

This significant investment underscores the region’s leadership in cutting-edge biotech innovation, particularly in epigenome editing and clinical research.

READ THE STORY at GeekWire »